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Abstract 
Motivation: Detailed and systematic understanding of the biological effects of millions of available 
compounds on living cells is a significant challenge. As most compounds impact multiple targets and pathways, 
traditional methods for analyzing structure-function relationships are not comprehensive enough. Therefore 
more advanced integrative models are needed for predicting biological effects elicited by specific chemical 
features. As a step towards creating such computational links we developed a data-driven chemical systems 
biology approach to comprehensively study the relationship of 76 structural 3D-descriptors (VolSurf, chemical 
space) of 1159 drugs with the gene expression responses (biological space) they elicited in three cancer cell 
lines. The analysis covering 11350 genes was based on data from the Connectivity Map. We decomposed these 
biological response profiles into components, each linked to a characteristic chemical descriptor profile. 
Results: The integrated quantitative analysis of the chemical and biological spaces was more informative about 
protein-target based drug similarity than either dataset separately. We identified ten major components that link 
distinct VolSurf features across multiple compounds to specific biological activity types. For example, 
component 2 (hydrophobic properties) strongly links to DNA damage response, while component 3 (hydrogen 
bonding) connects to metabolic stress. Individual structural and biological features were often linked to one cell 
line only, such as leukemia cells (HL-60) specifically responding to cardiac glycosides.  
Conclusions: In summary, our approach identified specific chemical structure properties shared across multiple 
drugs causing distinct biological responses. The decoding of such systematic chemical-biological relationships 
is necessary to build better models of drug effects, including unidentified types of molecular properties with 
strong biological effects. 
Background 
The mechanism of action of drugs at the biochemical level has 
typically been studied by investigating specific chemical 
properties of the drug and the biological properties of its specific 
target [1,2]. This is the standard paradigm in Quantitative 
Structure Activity Relationship (QSAR) studies, where 
multivariate mathematical models are used for modeling the 
relationships between a set of physiochemical or structural 
properties and biological activity. In previous QSAR studies, 
such as in the classical 3D-QSAR work by Cramer et al. [3], 
values of a single biological activity measure are predicted.  
However, biological responses at the cellular level are diverse 
and each drug typically binds to a multitude of targets in the 
cells and elicits a number of diverse effects. Systems-level 
approaches are thus needed to get a more comprehensive view of 
drug effects in living cells. Genome-wide massively multivariate 
description of the cellular responses caused by the drugs (Lamb 
et al., [4]) requires new kinds of tools for analysis and 
interpretation. 
Chemical systems biology has emerged at the interface of 
systems biology and chemical biology with the goal of 
constructing a systems-level understanding of drug actions. 
Systematic analysis of a network of drug effects, i.e. network 
pharmacology, offers great opportunities for drug design in the 
future [5]. Chemical systems biology has also been used to 
predict drug side effects [6] as well as in other types of 
toxicological analysis [7].  
Here, we take a complementary approach, by studying the 
impact of a host of chemical descriptors on the resulting detailed 
drug response profiles on a genome-wide scale. We link key 
structural components of the drug molecules, as defined by 3D 
VolSurf descriptors, with the consistent biological properties, as 
measured by comprehensive gene microarray expression 
profiles. We have developed a data-driven approach to analyze 
relationships between patterns in the specific chemical 
descriptors of the drugs on one hand, and patterns in the 
genome-wide biological expression responses on the other, as 
shown in Figure 1.  
As biological response data we use the Connectivity Map 
(CMap, [4,8]), which consists of gene expression measurements 
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from three cancer cell lines (MCF7, PC3 and HL60) treated with 
over a thousand different drug molecules (Figure 1.C). These 
data offer a unique view to the genome-wide responses of the 
cells to drug treatments and has been used to find new biological 
links e.g. between heat shock protein inhibitors, proteasome 
inhibitors, and topoisomerase inhibitors [8]. 
Our key assumption is that the chemical structure as encoded in 
the 3D descriptors of drugs impacts on the drug response 
resulting in specific patterns of gene expression. Furthermore, if 
there is any statistical relationship between the occurrence of 
patterns in the chemical space and the patterns in biological 
response space, those patterns are informative in forming 
hypotheses on the mechanisms of drug action. Given proper 
controls, the statistical responses can be attributed to the specific 
features of the chemicals tested out of a diverse drug library. In 
this paper we use comprehensive but readily interpretable 
models for finding the statistical dependencies. We search for 
distinct components that correlate the patterns in the chemical 
space with the biological response space. Assuming linear 
relationships, the task reduces to Canonical Correlation Analysis 
(CCA [9]) for searching for correlated components from the two 
data spaces (Figure 1.D). We visualize the components in a 
comprehensive way to facilitate interpretation (Figure 1.E and 
Figure 1.F) and validate them both qualitatively and 
quantitatively. 
Canonical Correlation Analysis was recently used for drug side 
effect prediction and drug discovery by Atias and Sharan [10]. 
They applied CCA to combine known side effect associations of 
drugs with (i) 2D structure fingerprints and (ii) bioactivity 
profiles of the chemicals. The CCA results from both 
combinations were then successfully used to predict side effects 
for the drugs, suggesting that CCA is effective in finding 
relevant components from heterogeneous data sources. 
Drugs generally act on a multitude of targets, several of which 
are connected to each phenotypic response. As most of this 
information is still unknown, modelling of the structure-target-
response over a large drug library is not a straightforward goal. 
Therefore in this study we model the structure-response 
relationships of 1159 drug molecules directly, with CCA 
components playing the role of unknown mechanistic processes. 
The non-availability of target information makes it important to 
select an appropriate type of chemical descriptors that allow 
capturing of generic response patterns. Many kinds of chemical 
descriptors are available for characterizing chemical structures in 
a quantitative way. Simple classical 2D fingerprints can be used 
to detect close analogs, but they would miss most if not all 
scaffold-hopping situations, where the different chemical entities 
give rise to similar pharmacophoric properties. Fingerprints and 
pure pharmacophoric descriptors require clearly defined 
individual targets, which are not known in many cases. In this 
piloting chemical and biological response study we use a set of 
VolSurf descriptors ([11]; Figure 1.A) that are ideal for 
capturing both structural similarities and general chemical 
features, such as solubility and permeation properties (ADMET: 
Absorption, Distribution, Metabolism, Excretion and Toxicology 
properties). Although VolSurf descriptors are not thought to 
explain detailed structure-activity relationships in the case of 
binding to single target, they offer a good overall interpretation 
of the molecular shape, hydrogen bonding, lipophilicity, and 
related properties, which are more conservative than individual 
binding cavities. It has also been shown that shape is a major 
factor when trying to find compounds with similar biological 
activity but dissimilar 2D structures [12]. 
Gene Expression
C: Connectivity Map expr. data, 11350 Genes over
1159 Compound treatments
A: 76 VolSurf Descriptors of
1159 Compounds
3D Chemical Descriptors Gene Set Database
Gene Set 
Enrichment Analysis
CCA
Integrated Components
E: "Eye Diagram", showing
relationships between VolSurf 
descriptors (left) and active gene sets 
(right) through CCA components (middle)
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Figure 1 - Data-driven search for statistical relationships between Chemical space (formed of VolSurf features) and Drug 
response space (gene expression). 
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The idea of correlating chemical structures with biological 
expression was introduced by Blower et al. in [13]. By 
combining 2D fingerprint data with biological activity profiles 
for the chemicals over 60 cancer cell lines (NCI60), and with 
steady-state gene expression measurements from those cell lines 
before drug treatments, they obtained indirect relationships 
between chemical substructures and the gene targets. In a more 
recent work, Cheng et al., [14] investigated correlations between 
the chemical structures, bioactivity profiles, and molecular 
targets for a set of 37 chemicals. This small-scale study 
demonstrated that combinations of biological activity and 
chemical structure information can provide insights into drug 
action mechanisms on a molecular level. 
By using the direct gene expression responses to a large set of 
drug treatments from Connectivity Map, along with 
comprehensive component-level decomposition of response 
profiles, we are able to make more direct observations on how 
compounds impact on cells and what features of the chemical 
molecules and the biological responses are correlated with one 
another.  
Results and Discussion  
We analysed the 1159 drug treatment gene expression responses 
of three cancer cell lines of the Connectivity Map, with the 
methods summarized in Figure 1 and detailed in Methods. The 
analysis decomposed into components the relationship between 
the “chemical space” of 76 chemical descriptors of each drug 
and the “biological space” of gene expression profiles of the 
drug response. We will call the components “CCA components” 
as the core method is Canonical Correlation Analysis (CCA). 
Each component relates a characteristic statistical pattern of gene 
expression with a pattern of the drug characteristics. In this 
section we analyse further the identified components and the 
statistical relationships they discovered. 
Quantitative validation of functional 
similarity of drug components 
We evaluate the biological relevance of the extracted CCA 
components by studying the functional similarity of drugs 
associated with each component. In particular, we measure the 
performance of the component model to retrieve similar drugs, 
as indicated by external data about their function, and compare it 
to retrieval based on either the biological or chemical data 
separately. Details of the validation procedure are described in 
Methods. The mean average precision obtained for the retrieval 
task on the four data sets (CCA components, chemical space, 
biological space as represented by GSEA and Gene expression) 
are plotted in Figure 2. 
The results show that retrieval based on the chemical space, i.e. 
VolSurf descriptors, performs clearly better than retrieval based 
on the biological space (activities of gene sets and genes), 
indicating that the chemical information is more relevant for 
evaluating the functional similarity of the chemicals. The 
biological space encoded by gene sets performs similarly to the 
original gene expression, indicating that the gene sets are a 
sensible encoding of the biological space; information lost due to 
dimensionality reduction is balanced by introduction of prior 
biological knowledge in the form of the sets. Finally, the 
combined space formed by the CCA components shows 
significantly better retrieval performance than either of the data 
spaces separately. The results are consistent over the range of the 
number of drugs considered in the retrieval task. These results 
show that CCA is able to extract and combine relevant 
information about the chemical structure and biological 
responses of the drugs, while filtering out biologically irrelevant 
structural information and also biological responses unrelated to 
the chemical characteristics. 
Response components and their 
interpretations 
We next analyze the top ten CCA components having the highest 
significant correlations between the spaces. Figure 3 summarizes 
the relationships between the VolSurf descriptors and the gene 
sets as captured by the components. Each component is divided 
into two subcomponents ‘A’ and ‘B’, where in the first the 
compounds have positive canonical score and in the second 
negative, even though the characteristic response patterns are 
otherwise the same (details in Methods).  
VolSurf descriptors, unlike more typically used 2D or 3D 
fingerprints and pharmacophores, do not have clear structural 
counterparts such as fragments or functional groups. Therefore, 
these descriptors are able to group together compounds with 
totally dissimilar chemical structures and yet having the same 
type of chemical properties. This is especially important in our 
study since the same biological activity may not have been 
created because of the same biological target protein but because 
of another target protein in the same pathway. Within a pathway, 
binding cavity properties may change, but general descriptors 
describing the size, lipophilicity, and shape are more 
conservative. Therefore VolSurf descriptors are better suited for 
classifying these aspects of the compounds. 
In the case of the 1st and 2nd components, the selected VolSurf 
descriptors are dominated by hydrophobic-related descriptors 
while other descriptors are not present. Another component with 
major hydrophobic contribution is 4th, but in this case also the  
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Figure 2 - Quantitative validation of functional similarity of 
drug components. The figure shows the mean average precision 
for retrieving functionally similar chemicals as a function of the 
number of top chemicals considered. Results are shown for three 
representations: CCA (red), Chemical space (green), and 
Biological space (GSEA: blue, Gene expression: grey). Error bars 
show one standard error of the mean precision. 
 
Manuscript under review 
 
 - 4 - 
 
 
molecular volume and surface area are having some effect. The 
3rd component is connected to hydrogen bonding, polar 
interactions, and dispersion-related descriptors. Components 5-7 
are mainly connected to “pharmacophoric” descriptors that are 
describing distribution of strong interaction points over the 
molecular space. Components 8 and 9 are both strongly 
influenced by integy-moments, describing imbalance of either 
hydrophobic or hydrophilic areas over the whole molecular 
volume.  Component 10 is mainly affected by shape and size-
related parameters, and also lipophilic integy moments. 
On the biological side of the components we observe that the 
enriched gene sets in component 1 indicate a mitogenic signaling 
response. Component 8 appears similar but has an additional link 
to cell adhesion signaling. Component 4 in turn very directly 
connects to cytoskeletal regulation and cell adhesion. While 
there appears to be a considerable overlap between compounds 
in components 2, 3 and 10, the enriched gene sets in component 
2 show a strong link to DNA damage response, 10 is associated 
with common cancer signals, and component 3 is associated with 
an anabolic response. Components 5 and 6 are connected to 
different differentiation events. Component 7 links to gene 
expression changes seen in GPCR signaling. Component 9 links 
to amino acid and nitrogen metabolism. 
We further extracted the significant genes in each component 
and performed GO enrichment analysis on them.  
Based on the Eye diagram (Figure 3) and lists of significant 
genes, gene sets, GO terms, and the top 20 compounds, we 
summarize the biological and chemical patterns in Table 1. 
Component examples: 3/3A – A cell stress 
component 
 We observed that in component 3, the top genes and gene sets 
indicate mostly mitochondrial and metabolic stress-related 
processes. Top gene sets associating with this component include 
many gene sets connecting to mitochondrial function (Figure 3).  
Similarly, on the gene level several known cell stress genes such 
as PGK1, PGD, and PRMT1 [15-17] are upregulated. A deeper 
look into the 3D structures of the top compounds in this 
component reveals a possibility of 4-12 hydrogen bonds in all of  
Table 1 - Summarized interpretation of top 10 components.  The pharmacophoric enrichment analysis (marked with “*”) was 
carried out over VolSurf features considered as a gold standard, and measuring enrichment of the list in a component by a 
hypergeometric test. 
Comp. Biological Interpretation Compounds in Group A Compounds in Group B VolSurf Interpretation 
1 
Classic growth factor 
signaling: (MAP and protein 
kinase signaling) 
Sulfonamides, antibiotics, 
carbonic anhydrase 
inhibitors 
Antipsychotic and 
antihistaminic compounds High lipophilicity 
2 DNA damage Contrast agents, 
antibiotics,  
DNA damaging agents, 
antimetabolites 
Strong lipophilic areas 
emphasized 
3 Stress response, mitochondrial  
and anabolic metabolism DNA damaging agents 
GPCR antagonists, ion 
channel blockers Polar interactions enriched 
4 Cytoskeleton, cell adhesion 
and migration 
GPCR liganda, 
macrocyclic cmpds and 
contrast agents 
Beta adrenergic agonists, 
other GPCR ligands  N/A 
5 Differentiation, EMT, 
stemness 
NSAIDS, cAMP signaling 
promoting compounds 
HDAC Inhibitors, HDAC-
like 
Significantly enriched with 
pharmacophoric features* 
6 Inflammatory and differentiation signaling N/A 
Protein synthesis inhibitors, 
anti-diabetics, cardiac 
glycosides 
Pharmacophoric features* 
7 GPCR and cytokine signaling  N/A  Cardiac glycosides, 
cephalosporins Pharmacophoric features* 
8 Growth factor and cell 
adhesion signaling Cardiac glycosides 
β-adrenergic agonists, Ca2+ 
channel blockers 
Integy-moment and significant 
pharmacophoric enriched* 
9 Amino acid and nitrogen 
metabolism Protein synthesis inhibitors Anti-diabetics 
Integy-moment and significant 
pharmacophoric enriched* 
10 Cancer signaling DNA damaging agents Corticosteroids, ionophores Size shape type descriptors 
 
Figure 3 - Relationships decomposed into components. “Eye 
diagram” showing the top 10 significant CCA components 
ordered by correlation from top to bottom (middle), VolSurf 
descriptors (left), and top gene sets (right). The CCA 
components are shown as circles, with numbers indicating the 
decreasing order of canonical correlation and letters A and B 
indicating subcomponents (A: positive canonical score, B: 
negative canonical score). The widths of the curves from the 
components to VolSurf descriptors and gene sets indicate the 
strength of the corresponding associations.  For VolSurf 
descriptors the subcomponent-specific activity is shown, 
whereas for the gene sets we show the overall activity in the 
component. (Zoom for details) 
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the top compounds of set 3A. Thus, these compounds may be 
able to affect proton transportation processes, which is in 
agreement with the biological interpretation that mitochondria 
act like proton pumps. As an example, Figure 4 shows the 
hydrogen bond donor and acceptor regions of azacitidine and 
idarubicin.  
 
To help understand how the biological variability caused by the 
drugs and the chemical features in component 3A compares with 
the intrinsic variability from one cell type to another, we 
visualize drug response transitions on MCF7 cells. Thirty 
different breast cancer cell types are used as references in their 
unperturbed condition (as described in Methods). The MCF7 
treatments from subcomponent 3A and the thirty independent 
breast cancer cells are plotted in Figure 5 using a recent 
multidimensional scaling method called NeRV [29,30]. NeRV 
shows these different cell instances mapped onto the 2-
dimensional display such that similarities are preserved as 
faithfully as possible. Subcomponent 3A contains many DNA-
damaging agents such as the DNA intercalating and 
topoisomerase inhibitory camptothecin, daunorubicin, and 
mitoxantrone, the CDK inhibitor alsterpaullone, the cardiac 
glycoside lanatoside C, which at high concentrations is likely to 
inhibit topoisomerases [18] the antimetabolite methotrexate, as 
well as rescinnamine, which has been suggested to induce a 
DNA damage response without itself inducing DNA damage 
[19] and the aromatase inhibitor letrozole. The NeRV plot based 
on the top changed genes in treated and untreated MCF7 cells as 
well as a panel of other breast cancer cell lines, shows that after 
treatment with these drugs, the gene expression of the luminal, 
ER-positive MCF7 cells starts to resemble the basal, ER-
negative breast cancer types. Interestingly, while MCF7 cells are 
relatively chromosomally stable, the drug-treatments make them 
appear like chromosomally unstable and intrinsic high DNA 
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Figure 6 - Finding interesting components. Heatmap across the 10 highest scoring significant CCA components: X-axis lists the 
top 30 significant genes in each subcomponent, while y-axis represents the top 20 scoring compounds in each. Two unique 
components 2B and 10A are zoomed in to show the detailed expression pattern along with 3D VolSurf descriptors (green areas are 
the lipophilic fields and the purple water fields). Only a subset (5 compounds and 10 genes) is shown in the zoomed version. 
 
Figure 4: Compounds high in hydrogen Bonding.  Azacitidine 
(left) and Idarubicin (right) showing H-bonding areas with blue 
(hydrogen-bond donor) and red (hydrogen-bond acceptor). 
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Figure 5 - 3A drug transitions.  NeRV visualization showing 
Drug Treatment Transitions. Lines indicate the transition from 
Pretreated MCF7 to treated MCF7 cells. 
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damage cell lines such as HCC1937 or MDA-MB-231.  Cell 
stress is an emerging cancer therapy target and it is interesting 
that a) this subcomponent including topoisomerase inhibitors, 
antimetabolites and CDK inhibitors induces stress-related 
metabolic responses in MCF7 cells similar to what is seen in a 
basal level in other, more malignant and undifferentiated breast 
cancer cells, and b) it raises the hypothesis that the compounds 
in this subcomponent could be combined with cell stress 
targeting compounds. This finding is strengthened by the fact 
that many of the top upregulated genes in the 3A subcomponent; 
ACHY, CDC37, GPI, ME2, PMRT1, P4HB, PGD, and PGK1 
are also overexpressed in breast cancers as compared to normal 
tissue. 
2B & 10A – Functionally similar but gene-
wise different responses 
We observe that component groups 2B, 3A, and 10A share 
several compounds such as the DNA-intercalating topoisomerase 
inhibitors mitoxantrone and irinotecan, the cyclin-dependent 
kinase (CDK) inhibitors alsterpaullone and GW-8510, and the 
antimetabolites methotrexate and azacitidine, 5 of the top 20 
between each paired group. Most of the non-overlapping 
compounds in each component group are not linked functionally 
or structurally in any obvious way, on the other hand. To verify 
that the components capture different phenomena despite sharing 
several compounds, we compute chemical composition and 
biological similarity matrices over all component pairs. We use 
the Tanimoto similarity measure to compute overlap between the 
top 30 genes of each subcomponent pair. The analysis of 
biological similarity between these subcomponents with 
compound overlap (out of top 20 compounds for each 
component) indicates that there is minimal biological and 
chemical sharing between any two components. Almost all 
component pairs that are highly biologically similar have a non-
significant and low chemical composition similarity, and vice 
versa. This is a strong indication that we have identified sets of 
VolSurf descriptors that link to different biological responses. In 
some cases, several of these features can be identified in a single 
molecule like the etidronic acid, which is linked to both 
components 3 and 6. The chemical properties of component 6 
are connected with pharmacophoric features and component 3 
with hydrogen bonding, while biologically the components are 
related to differentiation and stress response, respectively. 
To get a deeper view of the underlying biological response 
mechanisms we explore the response patterns of the components 
using heatmaps. In the first heatmap, we consider the most active 
genes in a subcomponent and plot their expression levels across 
the top compounds of every subcomponent (Figure 6 ). In the 
figure we search for the subcomponents that have a unique 
expression pattern across other subcomponents in a column. 
Components 2B and 10A show a unique structure. These seem to 
represent two separate aspects of DNA damage response, which 
are connected to two separate molecular features; hydrophobicity 
in component 2B and shape-type VolSurf descriptors in 
component 10A. The gene expression changes in both 
subcomponents are strongly linked to a DNA damage and 
mitotic arrest response with many proto-oncogenic cell division 
and mitogenic signaling genes being down regulated (Figure 6 ). 
The same genes are commonly seen upregulated in cancers and 
many of them have been and are pursued as drug targets. 
Therefore both the components are similar on a larger biological 
scale, but do in fact have little gene-wise overlap. 
To validate these hypotheses, we checked for reported growth 
inhibition for the top 20 chemicals in these two subcomponents 
in the NCI/DTP in vitro cell line testing database (NCI60 testing 
program, http://dtp.nci.nih.gov/docs/cancer/cancer_data.html). 
Four compounds from 2B and 10 from 10A were represented in 
the NCI60 datasets (Table 2). For almost all of the compounds 
for which NCI60 data are available, in CMap the compounds 
were used at doses that very effectively will stop the cells from 
growing or kill them. 
7B – A leukemia-specific subcomponent  
Based on studying the heatmaps, 7B is another interesting 
subcomponent: It has a dominant effect on HL60 as compared to 
MCF7 and PC3, indicating that this subcomponent and the link 
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Figure 7 - Heatmap for subcomponent 7B. Y-axis lists the top 
10 active compounds in the component, replicated over the three 
cell lines, while the X-axis lists the most significantly active 
genes in the component. The genes are clearly activated 
systematically and exclusively in the HL60 cell line, hence 
indicating an HL60 specific response. 
Table 2: Growth Inhibition verification of 2B/10A 
Compounds. GI50 values (drug concentration causing a 50% 
growth inhibition) from NCI/DTP are shown along with the 
corresponding concentrations used in the Connectivity Map 
(CMap) data. By comparing the GI50 and CMap values we can 
get an idea of expected cell killing effect of the drug in the 
CMap data. Drugs that are expected to eventually kill the cells 
are shown in bold. Concentration values are in µM scales. 
Chemical CMap 
(µM) 
GI50  
(µM) 
Subcomponent Cell line 
berberine 10 25.1 2B MCF7 
irinotecan 100 6.3 2B, 10A MCF7 
mitoxantrone 7.9 0.004 2B MCF7 
amiodarone 6.3 4.0* 2B PC3 
8-azaguanine 25.1 0.32 10A HL60 
apigenin 15.9 25.1 10A HL60 
azacitidine 15.9 0.79 10A PC3 
camptothecin 12.6 <0.01** 10A MCF7 
chrysin 15.9 15.8*** 10A MCF7 
methotrexate 7.9 0.03 10A MCF7 
thioguanosine 12.6 0.32 10A MCF7 
esculetin 25.1 >100** 10A HL60 
fulvestrant 1.0 >100** 10A PC3 
* GI50 value at the end of the tested range 
** Mean of GI50 values from HL60 and MCF7 cell lines 
*** Value from HL60 cell line 
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between structure and gene expression may be specific for 
leukemic cells and leukemic-specific molecular targets.  
Figure 7 shows the activity of most significant genes (columns) 
corresponding to the top compounds (rows) across the three cell 
lines. The top drugs are mainly cardiac glycosides and these 
drugs are known to have a strong toxic effect on leukemic cells 
at the concentrations used.  It is worth noting that FLT3LG 
(FLT3 ligand) is one of the most significantly up-regulated 
genes. The FLT3 receptor, to which FLT3LG binds, is an 
emerging target in leukemia [20]. 
Conclusions  
We have introduced a chemical systems biology approach for 
analyzing the complex relationship patterns between chemical 
structures of drug molecules and their genome-wide responses in 
cells. With Canonical Correlation Analysis, we are able to find 
statistical dependencies between the two data spaces in the form 
of correlated components. We have demonstrated quantitatively 
that these components are more informative about drug 
similarity than either chemical or biological data separately.  
In our study, we used gene sets to introduce biological 
knowledge into the analysis. Iorio et al. [8] have recently got 
very promising results with an alternative method of analyzing 
gene expression responses. It is an interesting and non-
straightforward research question whether that approach can be 
generalized to searching for structure-response relationships. 
We have also demonstrated the use of advanced visualization 
methods to facilitate detailed interpretation of the chemical and 
biological characteristics of the components. Our findings show 
connections between the biological responses of many known 
drug groups to their general chemical properties (Table 1). As an 
example of the ability of the model to discover detailed drug 
response mechanisms we were able to separate different DNA 
damage responses that appear to be driven by different chemical 
features in compound sets having considerable overlap. 
Subcomponents 2B, 3A, and 10A all contain classic 
chemotherapeutic and DNA damaging agents as described in the 
results section. Strikingly, subcomponents 2B and 10A are 
driven primarily by hydrophobic/lipophilic descriptors and are 
more similar in their biological output. They both connect to the 
downregulation of many proto-oncogenic and mitotic genes but 
notably still through almost entirely non-overlapping gene sets 
and genes. Subcomponent 3A, on the other hand, which is 
connected to hydrogen bonding and hydrophilic features, 
connects to a very different cellular response: the turning on of 
many stress-induced “defense” genes. In other words, we 
document how within the same compound or related compounds, 
hydrophobic and size features drive a mitotic arrest response 
while hydrogen bonding and hydrophilic features drive a 
reparative response. This knowledge, in combination with gene 
expression data in the solid tumors may allow us to design and 
utilize the chemotherapeutic agents with the appropriate balance 
of hydrophilic, size and hydrogen bonding for each cancer 
patient to hit the correct balance between anti-growths to damage 
response induction for best possible efficacy. 
Methods 
Gene Expression Data 
We used the Connectivity Map gene expression profile data set 
as biological response profiles to drug treatments, forming the 
biological space. Instead of the rank-based procedure of the 
original Connectivity Map paper, we used a different 
preprocessing method since ranking amplifies noise. Even small 
differences in low intensities, which contain mostly noise are 
ranked, and this has a significant impact on the identification of 
differentially expressed genes. Hence, we downloaded the raw 
data files in original CEL-format, from 
http://www.broadinstitute.org/cmap/, which we RMA-
normalized [21] before computing differential expression. We 
used expression profiles from the most abundant microarray 
platform (HT-HG-U133A) in the data collection. Differential 
expression was then taken with respect to the control 
measurements in each measurement batch. In the case of 
multiple controls per batch, we formed a more robust control by 
removing as an outlier the control with the highest Euclidean 
distance to the other controls, and then used the mean of the rest 
as the controls. To further reduce the noise in the expression 
data, we discarded 5% of the genes having the highest variance 
in the control measurements, that is, genes having high level of 
variation unrelated to chemical responses. As simple means of 
balancing between the varying sample sizes for different 
chemicals in the CMap data, we chose for each chemical the one 
instance with the strongest effect, measured with the highest 
norm of response, on the cell line for further analysis. The 
resulting gene expression data consisted of profiles for 1159 
compounds over 11,350 genes. 
To bring in prior knowledge of biological responses, and to 
reduce the dimensionality of the gene expression data, we 
performed Gene Set Enrichment Analysis (GSEA). GSEA gives 
as output for each gene set the direction (positive/negative) and 
strength of the activity, as measured by the false discovery rate 
(FDR) q-values, ranging from 0 (indicating highest activity) to 1. 
We transformed the q-values for the CCA by first inverting the 
q-values such that 1 indicates the highest activity, and then 
further mirroring q-values for the negatively activated gene sets 
with respect to zero to take the sign of activity into account. This 
results in a reasonably unimodal distribution of the data around 
zero, with higher positive and negative values indicating higher 
positive and negative activation of the gene sets, respectively. In 
the resulting data we have biological activation profiles over 
1321 gene sets for 1159 distinct chemicals (see Figure 1.B). 
As the gene sets, we used the C2 collection (curated gene sets 
v2.5) from the Molecular Signatures Database 
(http://www.broadinstitute.org/gsea/msigdb/). The extensive 
collection of gene sets covered 90% genes in our data and is thus 
a sensible representation of the biological space. GSEA was 
computed with the Java software package version 2-2.05 
(http://www.broadinstitute.org/gsea). 
Chemical descriptors 
The chemical space was formed by representing each chemical 
with a set of descriptors of its structure and function. In the 
analysis, the chemical similarity will be dependent on the 
selected descriptors and thus the selection is of utmost 
importance. This is especially true when the aim is to find small 
molecules that share targets and biological functions regardless 
of structural similarity. We use the VolSurf descriptors, 
calculated using MOE version 2009.10 
(http://www.chemcomp.com/software.htm). Original sdf-files 
were translated into 3D using Maestro/LigPrep (Maestro version 
9.0) since VolSurf descriptors are based on 3D molecular fields. 
The resulting data contains 76 descriptors for each chemical.  
Canonical Correlation Analysis 
Drug action mechanisms are indirectly visible in relationships 
between the chemical properties of the drug molecules and the 
biological response profiles. We carry out a data-driven search 
for such relationships with a method that searches for correlated 
components in the two spaces, as shown in Figure 1. 
Canonical Correlation Analysis (CCA [9]) is a multivariate 
statistical model for studying the interrelationships between two 
sets of variables. CCA explores correlations between the two 
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spaces whose role in the analysis is strictly symmetric, whereas 
classical regression approaches like Partial Least Squares [22] 
typically explain one or possibly several response variables in 
one space by a set of independent variables in the other one. The 
result of the CCA analysis is an underlying component subspace 
relating chemical descriptors with gene sets. 
Let us consider two matrices X and Y, of the size of n x p and n x 
q, representing the chemical and biological spaces. The rows 
represent the samples and the columns are the features (gene set 
activation values or chemical descriptors). In the following we 
describe the CCA learning algorithm as a stepwise process. 
First, two projection vectors w1 and v1 are sought such that they 
maximize the correlation P1 between components of data formed 
by projecting the data onto them,  
 
subject to the constraint that the variance of the components is 
normalized, i.e., var(Xw1) = var(Yv1) = 1. 
The resulting linear combinations Xw1 and Yv1 are called the first 
canonical variates or components, and P1 is referred to as the 
first canonical correlation. The first canonical variates explain 
the maximum possible shared variance of the two spaces along a 
single linear pair of projections: w1 and v1. 
The next canonical variates and correlations can be found as 
follows. For each successive step s = 2,3,…min(p,q), the 
projection vectors (ws,vs), can be found by maximizing 
 
subject to the constraint var(Xws) = var(Yvs) = 1, and with a 
further constraint of uncorrelatedness between different 
components. 
Let Cxx = XXT and Cyy = YYT denote the scaled sample 
covariance matrices for the two input spaces, and Cxy = XYT the 
sample cross-covariance. Then the first canonical correlation is 
 
If Cxx and Cyy are invertible the vectors w1 and v1 maximizing 
the above equation can be found. Generally, in omics data and 
also in our study, the number of genes/gene sets is large 
compared to the number of experiments. In such cases the 
classical CCA solution may not exist or it can be very sensitive 
to collinearities among the variables. This issue can be addressed 
by introducing regularization [23-25], i.e., by penalizing the 
norms of the associated vectors. Hence, we seek projection 
vectors that maximize the penalized correlation 
 
The regularization coefficients L1 and L2 were estimated with 20-
fold cross validation over a grid of values, while maximizing the 
retrieval performance on known drug properties. The retrieval 
procedure and performance measure are described in the drug 
similarity validation section below. In each fold, the model was 
first applied to a training data set, and the test data were then 
projected to the obtained components. Estimated regularization 
parameter values were L1 = 100 and L2 = 0.001. We used R-
package “CCA” [24]. 
Drug similarity validation procedure  
To quantitatively validate the performance of the component 
model in extracting functionally similar drugs, we carried out the 
following analysis. For a given data set, we first computed 
pairwise similarities of drugs. In practice, we used each chemical 
in turn as a query, and ranked the other chemicals based on their 
similarity to the query. For the similarity measure, we had three 
alternatives, similarity in the CCA component space, in the 
biological space, and in the chemical space. Finally, we 
computed the average precision of retrieving chemicals that are 
functionally similar to the query, i.e. share at least one known 
property in an external validation set. We report the mean of the 
average precisions for all chemicals. We repeat the results as a 
function of the number of the top ranked chemicals used to 
compute the average precision (from 5 to 100). 
We constructed the external validation set about the functional 
similarity of the drugs from their known protein targets and ATC 
(Anatomical Therapeutic Chemical, 
http://www.whocc.no/atc_ddd_index/) codes. Drug target 
information was obtained from ChEMBL 
(https://www.ebi.ac.uk/chembl/), DrugBank 
(http://www.drugbank.ca/), DUD (http://dud.docking.org/), and 
ZINC (http://zinc.docking.org/). We additionally extracted 
targets and ATC codes for the CMap chemicals from the 
supplementary material provided in [8]. From the ATC codes we 
used the fourth level information, indicating the 
chemical/therapeutic/pharmacological subgroup and hence high 
similarity of drugs. In total we have 4427 associations between 
821 CMap chemicals and 796 targets or ATC codes. 
Visualizing through an “Eye diagram”: 
Relationship between gene sets, extracted 
components, and VolSurf descriptors 
The CCA components summarize statistical relationships 
between the chemical and biological spaces. The relationships 
can be visualized as in Figure 1 and Figure 3: The components in 
the middle are connected to the chemical descriptors that activate 
them (left) and to the gene sets that are differentially expressed 
when the component is active. We selected the top 10 significant 
components from the CCA model for the visualizations. The 
significances of the components were estimated by a 
permutation test, using the observed correlations as a test 
statistic. The samples in one of the spaces were randomly 
rearranged removing the relationship with the other space. One 
thousand such random permutations were formed and their 
canonical correlations computed. Component significances were 
then determined as the proportion of random correlations that are 
greater than the observed correlation. 
The components were further split into two subcomponents 
labeled ‘A’ and ‘B’, in A the canonical scores are positive and in 
B negative. Compounds in the two subcomponents behave in the 
opposite fashion on the gene sets and VolSurf features, such that 
when one of the subcomponents activates some biological 
processes, the other either has no effect or deactivates them. For 
visual clarity the eye diagram shows only the top 10 correlated 
gene sets for each component, out of the 1321 gene sets used. 
All 76 VolSurf features are shown. The eye diagram was 
originally introduced in [26] for visualizing component models. 
Differentially expressed genes and GO 
enrichment 
To get a comprehensive view of the biology in each component 
we extracted the genes and Gene Ontology classes active in each 
( )1 , 1 11 1max cor , ,w vP Xw Yv=
( ),max cor , ,s ss w v s sP Xw Yv=
1 1 1 1 1 1 1 .
T T T
xy xx yyP w C v w C w v C v=
1 1
1
1 1 1 1 1 1 2 1
.
T
xy
T T
xx yy
w C v
P
w C w L w v C v L v
=
+ +
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one of them. For each component, we took the top 20 positively 
and top 20 negatively correlated gene sets and listed the genes in 
them. The differential expression of these genes was tested for 
activation/repression of the gene in the top 10 active compounds 
in the component using a regularized t-test [27]. The genes 
having p-values < 0.05 were considered to be significantly 
activated by the compounds in the component. This procedure 
ensures that the extracted genes are most representative of the 
top correlated gene sets in the component, hence contributing the 
most to the canonical correlation. 
The component-specific list of significantly differentially 
expressed genes was used to compute the corresponding Gene 
Ontology Enrichment for each component. Enrichment was 
computed for Biological Process classes using GOstats R-
package (www.bioconductor.org/help/bioc-
views/release/bioc/html/GOstats.html).  
Characterizing drug response on breast 
cancer cells 
We investigated if the components reveal interesting patterns in 
the responses to drugs, by plotting the transitions caused by each 
drug in the gene subspace defined by the component. This was 
done by extracting the 100 most significant genes as an effective 
representative of changes caused by treatments in the genome 
(using the procedure described in the above sub-section). The 
profiles of 30 independent cell lines in a steady-state, 
unperturbed conditions, were included to act as references for 
calibrating the display. These independent breast cancer cell 
lines were obtained from ArrayExpress experiment ID E-
MTAB-37 (www.ebi.ac.uk/arrayexpress) with replicates merged 
to make a single representation for each of the cell types. All cell 
lines were annotated as BasalA, BasalB, Luminal, or progenitor 
using classifications by Kuemmerle et al.,[28]. Only MCF7 
(breast cancer) treatments were used from CMap data. 
The breast cancer cell line and CMap data come from different 
Affymetrix platforms, HG-U133plus_2.0 and HT-HG-U133A, 
respectively. We therefore normalized them separately by 
computing differential expression as the expression value 
divided by the mean of each gene within the platform. These 
normalized data were scaled using log2.  
Both the CMap-selected instances and breast cancer cell data 
were collected into a single matrix. To visualize the transitions, 
pairwise correlation similarities were computed over this matrix 
and plotted using the state-of-the-art non-linear dimensionality 
reduction and visualization tool NeRV [29,30]. The result is a 
mapping of the high-dimensional expression profiles to a two-
dimensional display for easier visualization, such that if two 
points are similar in the visualization, they can be trusted to have 
been similar before the projections also. NeRV visualization of 
component 3A, which is analyzed in the Results, is shown in 
Figure 5 . 
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